Dr Karine Tremblay Université de Sherbrooke, Canada
She is a Ph.D. specializing in complex trait genetic epidemiology, with a comprehensive skill set encompassing laboratory molecular genetics, biostatistics, and clinical research. Her contributions include identifying new genetic associations in asthma and co-authoring clinical studies in applied pharmacogenetics, notably with publications in NEJM. With expertise in coordinating over 10 clinical trials across various phases, she has established herself as a skilled investigator applying the highest clinical research standards. As an independent researcher, she has contributed to knowledge transfer on the barriers to pharmacogenomics implementation in clinical practice, evident in her work with focus groups of physicians, pharmacists, and patients.
đEducation:
She embarked on her academic journey at UniversitĂ© du QuĂ©bec Ă Chicoutimi, Canada, from September 1998 to May 2002, earning her Bachelor’s degree in Biology. Building on this foundation, she pursued her Master’s in Experimental Medicine at UniversitĂ© Laval, QuĂ©bec, from September 2002 to December 2004. Her academic journey continued at UniversitĂ© Laval, where she achieved her Ph.D. in Experimental Medicine from September 2004 to May 2009. Following her doctoral studies, she engaged in a postdoctoral fellowship in Applied Pharmacogenetics at the Centre de mĂ©decine gĂ©nique communautaire, affiliated with the UniversitĂ© de MontrĂ©al, from September 2009 to June 2014. Throughout her educational and postdoctoral endeavors, she demonstrated a commitment to advancing knowledge in the field of medicine.
đ Profile Links:
Awards and Honors:
Throughout her academic and research career, she has been recognized for her outstanding contributions and dedication. From June 2020 to June 2024, she was awarded the prestigious Chercheurs-boursier Junior 1 grant by the Fonds de recherche du QuĂ©bec – SantĂ© (FRQ-S), amounting to 295,451 CAD, acknowledging her excellence in translational research. Simultaneously, she served as a Trainee in the UnitĂ© de soutien SSA (SystĂšme de SantĂ© Apprenant) du QuĂ©bec, jointly appointed by FRQ-S, further showcasing her commitment to advancing healthcare knowledge. Her academic journey includes noteworthy postdoctoral training scholarships, including a renewal from FRQ-S in 2013/1-2014/6 and significant support from the Heart and Stroke Foundation of Canada (HSFC) from 2010/7-2012/12. She also received accolades such as the Best Scientific Presentation award in 2008/5 from RĂ©seau en MĂ©decine GĂ©nique AppliquĂ©e (RMGA) du FRQ-S and a Doctoral Scholarship from Fondation de l’UniversitĂ© Laval in 2007/5-2007/7. These accolades underscore her exceptional achievements and commitment to advancing scientific knowledge in the field of medicine.
Academic Positions:
Since June 2020, she has held the position of Assistant Professor on a Tenure Track at the Université de Sherbrooke, located in Sherbrooke, Quebec, Canada. Within the esteemed Faculty of Medicine and Health Sciences, she specializes in Pharmacology-Physiology, contributing to the academic and research landscape. Her role as an Assistant Professor reflects her commitment to education and the pursuit of knowledge in the field. Building on this academic foundation, she expanded her contributions by becoming a Regular Researcher at the Institut de pharmacologie de Sherbrooke, further solidifying her presence in the vibrant research community of Sherbrooke, Quebec. In this capacity, she engages in impactful research endeavors, enhancing the understanding of pharmacology and contributing valuable insights to the scientific community. Her dual roles as an academician and researcher underscore her dedication to advancing both education and cutting-edge research in the field of pharmacology and physiology. Through her tenure-track position and research appointment, she continues to play a vital role in shaping the academic and scientific landscape at both the institutional and community levels.
Publications:
- Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia Cited By: 534, Published By: 2015
- Targeting APOC3 in the familial chylomicronemia syndrome Cited By: 464, Published By: 2014
- Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial Cited By: 452, Published By: 2013
- Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency Cited By: 142, Published By: 2010
- Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis Cited By: 102, Published By: 2016
- Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome Cited By: 99, Published By: 2015
- Replication of an association between 17q21 SNPs and asthma in a French-Canadian familial collection Cited By: 99, Published By: 2008
- Etiology and risk of lactescent plasma and severe hypertriglyceridemia  Cited By: 71, Published By: 2011
- Association of urokinase-type plasminogen activator with asthma and atopy Cited By: 64, Published By: 2007
- Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients Cited By: 62, Published By: 2019